Effectiveness of a Quality Improvement Intervention on Reperfusion Treatment for Patients With Acute Ischemic Stroke
Authors: Chun-Juan Wang, Hong-Qiu Gu, Li-Xia Zong, Xin-Miao Zhang, Qi Zhou, Yong Jiang, Hao Li, Xia Meng, Xin Yang, Meng Wang, Xiao-Chuan Huo, Run-Qi Wangqin, Yu-Zhang Bei, Xiu-Hui Qi, Xiao-Yun Liu, Shi-Qiang Hu, Zhi-Min Wang, Xing-Quan Zhao, Yi-Long Wang, Li-Ping Liu, Xu-Dong Ma, Louise Morgan, Ying Xian, Lee H. Schwamm, Yong-Jun Wang, Zi-Xiao Li, Qingcheng Yang, Guangsheng Chen, Qianli Ma, Xiaobo Li, Jun Chen, Xiuli Zhao, Hongping Wang, Xiaoyuan Niu, Jianhua Xu, Lile Zhao, Zicheng Wang, Danqin Huang, Xiaoping Jin, Shengli Chen, Jianhua Li, Juming Yu, Ping Liu, Guozhong Li, Yanlei Hao, Guancheng Yang, Xiaoxin Huang, Chengfang Zhou, Junsu Yang, Jun Gu, Peng Sun, Zaiyu Guo, Guoping Ma, Guohua Chen, Mingshan Tang, Ning Wang, Lixia Chen, Juntao Li, Aiwu Li, Song Li, Minghua Cao, Jianqiang Guo, Youquan Ren, Tong Li, Lihong Zhang, Zhaoming Xie, Junlin Dong, Xiangfeng Kong, Hui Liang, Yan Zhang
Journal: JAMA Network Open (2023)

Importance Reperfusion therapy is the most effective treatment for acute ischemic stroke but remains underused in China. Objective To evaluate the effect of a problem-oriented, culturally adapted, targeted quality improvement intervention on reperfusion therapy for patients with acute ischemic stroke in China. Design, Setting, and Participants In this stepped-wedge cluster randomized clinical trial, patients from 16 secondary and 33 tertiary hospitals in China with acute ischemic stroke within 6 hours of symptom onset were consecutively recruited between July 1, 2018, and June 30, 2020. Interventions Hospitals were randomly assigned to 1 of 3 sequences to receive the targeted quality improvement intervention (n = 5689), in which workflow reconstruction was promoted to reduce in-hospital reperfusion treatment delays, or usual care (n = 6443), in which conventional stroke care was left to the discretion of the stroke team. Main Outcomes and Measures The primary outcome was the reperfusion therapy rate, a composite outcome of intravenous recombinant tissue plasminogen activator (IV rtPA) or endovascular thrombectomy (EVT) for eligible patients who arrived within 3.5 or 4.5 hours of symptom onset. Secondary outcomes were the IV rtPA administration rate among eligible patients who arrived within 3.5 hours of symptom onset, the EVT rate among eligible participants who arrived within 4.5 hours of symptom onset, the proportion of patients with door-to-needle time within 60 minutes, the proportion of patients with door-to-puncture time within 90 minutes, in-hospital mortality, and 3-month disability as measured by a modified Rankin Scale score greater than 2. Results All 12 132 eligible patients (mean [SD] age, 66 [12.1] years; 7759 male [64.0%]) completed the trial. The reperfusion rate was 53.5% (3046 of 5689) for the eligible patients in the intervention period and 43.9% (2830 of 6443) in the control period. No significant improvement in primary outcomes was found for the intervention after adjusting for cluster, period, and imbalanced baseline covariates (adjusted risk difference [ARD], 5.5%; 95% CI, −8.0% to 19.0%; adjusted odds ratio [AOR], 1.26; 95% CI, 0.72-2.21) or for the secondary outcomes. However, significant improvements were found in secondary hospitals for reperfusion therapy (1081 of 1870 patients [57.8%] vs 945 of 2022 patients [42.9%]; ARD, 19.0%; 95% CI, 6.4%-31.6%; AOR, 2.24; 95% CI, 1.29-3.88), IV rtPA administration (1062 of 1826 patients [58.2%] vs 916 of 2170 patients [42.2%]; ARD, 20.3%; 95% CI, 7.4%-33.1%; AOR, 2.37; 95% CI, 1.34-4.19), and EVT (51 of 231 patients [22.1%] vs 37 of 259 patients [14.3%]; ARD, 13.6%; 95% CI, 1.0%-26.3%; AOR, 3.03; 95% CI, 1.11-8.25) in subgroup analyses. Conclusions and Relevance In this stepped-wedge cluster randomized clinical trial of patients with acute ischemic stroke in China, the use of a targeted quality improvement intervention compared with usual care did not improve the reperfusion therapy rate. However, the intervention may be effective in secondary hospitals. Trial Registration ClinicalTrials.gov Identifier: NCT03578107